PAA
AGIO icon

Peregrine Asset Advisers’s Agios Pharmaceuticals AGIO Stock Holding History

Peregrine Asset Advisers’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-5,540
Closed -$621K – 130
2014
Q4 		$621K Buy
+5,540
New +$495K 0.44% 58

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CGT
Capital Guardian Trust Los Angeles, California $7.42B AUM 13.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Peregrine Asset Advisers's AGIO Position: Q1 2015 in Review

Peregrine Asset Advisers sold out of Agios Pharmaceuticals (AGIO) in Q1 2015, closing a stake of 5,540 shares — an estimated $621K sold.

Peregrine Asset Advisers first reported a position in AGIO in Q4 2014 and held it in 1 quarter. The position peaked at $621K in Q4 2014. 152 funds tracked by Wall St. Rank hold AGIO as of Q1 2015.

  • Peregrine Asset Advisers reported no remaining Agios Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Peregrine Asset Advisers sold 5,540 Agios Pharmaceuticals shares in Q1 2015, an estimated $621K.
  • Peregrine Asset Advisers first reported a position in Agios Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • Peregrine Asset Advisers's Agios Pharmaceuticals position peaked at $621K in Q4 2014.
  • 152 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2015.

Based on Peregrine Asset Advisers's 13F filing for Q1 2015, filed 13 May 2015.